Review

Extracellular Vesicles as Pro- and Anti-inflammatory Mediators, Biomarkers and Potential Therapeutic Agents in Multiple Sclerosis

Mallahalli. S Manu*, Hirohiko Hohjoh, Takashi Yamamura

1Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502 Japan. 2Department of Molecular Pharmacology, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Kodaira, Tokyo, 187-8502 Japan.

[Received February 22, 2021; Revised May 10, 2021; Accepted May 11, 2021]

ABSTRACT: Multiple sclerosis (MS) is an autoimmune neurodegenerative disease of the central nervous system (CNS) characterized by multiple demyelinating lesions in the spinal cord and brain. Neuronal disruption caused by myelin loss or demyelination, which may accompany axonal changes, leads to multiple neurological symptoms. They may transiently appear for weeks during periods of disease worsening (relapse) in relapsing-remitting form of MS (RRMS). Although a number of genetic, metabolic and environmental factors influencing the development of MS have been identified, the precise mechanisms involved in the CNS tissue damage in MS are still poorly understood. Recent studies have revealed a significant role of circulating extracellular vesicles (EVs) in many diseases. EVs are known to serve as a cellular communication tool between two cell types either in close proximity or in different parts of the body. During the recent development in understanding of the pathogenesis of MS, studies have revealed the possible role of EVs in MS. Furthermore, circulating EVs can be used as a biomarker for monitoring disease progression and activity of MS, and they can also be therapeutic reagents or targets of therapy. In this review we overview and discuss in detail about generation of EVs and their diversified roles in MS.

Key words: autoimmunity, extracellular vesicles, Multiple sclerosis, exosomes, microRNA

1. Introduction

Multiple sclerosis (MS) is one of the major and common progressive neurological disorders, which affects 2.8 million people around the world in 2020. This number is increased by 20% compared to 2013 data given by Multiple Sclerosis International Federation (MSIF). An alarming increase in the MS numbers in the last two decades is observed in many countries and this rise indicates the necessity and importance of MS research to understand its pathophysiology in order to overcome the suffering.

MS is a devastating disease of the central nervous system (CNS) caused by autoimmune responses to CNS antigens such as myelin basic protein, leading to the neuronal damage and formation of demyelinating plaques in the brain, spinal cord and optic nerves. The immune mediated damage in the CNS of MS patients is caused by complicated interactions among many immune cell types, including T cells, B cells, dendritic cells (DC),

*Correspondence should be addressed to: Dr. Mallahalli. S Manu and Dr. Takashi Yamamura, National Center of Neurology and Psychiatry, Kodaira, Tokyo 187-8502, Japan. E-mail: mallahallimanu@gmail.com (Dr. Mallahalli.S Manu) and yamamura@ncnp.go.jp (Dr. Takashi Yamamura).

Copyright: © 2021 Manu M et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The pathogenesis of MS is associated with developmental stage changes. EVs are further classified into microvesicles and exosomes, which may serve as a molecular marker for apoptotic cells. Studies conducted during the past two decades have confirmed their role in various human diseases including inflammatory diseases. There is substantial evidence indicating the involvement of EVs in MS pathophysiology, but the functional efficacy of EVs is dependent on their surface molecules and their cargo. Therefore, they can be both beneficial and harmful. Hence, it has been a great challenge to elucidate their roles in MS disease progression. Currently we have substantial evidence to indicate the role of genetic, metabolic and environmental factors that are interconnected to generate hazardous autoimmune responses causing MS.

Extracellular vesicles (EVs) are the small non-nucleated vesicles derived from various cell types. EVs are usually filled with biomolecules such as proteins, small nucleotide sequence called microRNAs (miRNAs) that are known to serve as regulatory components in several biological responses. Studies conducted during the past two decades have confirmed their role in various human diseases including inflammatory diseases. There is substantial evidence indicating the involvement of EVs in MS pathophysiology, but the functional efficacy of EVs is dependent on their surface molecules and their cargo. Therefore, they can be both beneficial and harmful. Hence, it has been a great challenge to elucidate their roles in MS disease progression. This review overviews the latest research on EVs, which directly address their involvement in MS pathology and their signature in MS progression. Also, we have attempted to consolidate the available information on how EVs from the different sources and cargo can be therapeutically utilized in MS. Lastly, we have discussed the limitation and future prospective of EVs research with significant implication to MS.

2. EVs generation and their classification

EVs are the small vesicles mostly of less than 1000 nm in size derived from live cells, whereas apoptotic bodies of a similar size (about 50-5000 nm) are derived from dying (apoptotic) cells. EVs are further classified into microvesicles and exosomes of 100-1000 nm and 50-150 nm in size, respectively. Apoptotic cells often display phosphatidylserine (PS) on their cell membrane, and apoptotic bodies also carry PS on their outer membrane, which may serve as a molecular marker for apoptotic bodies. In contrast, microvesicles are generated by budding from the cell membrane, and selectins, integrins and the CD40 ligand may be used as markers for the microvesicles. Exosomes, on the other hand, are formed by inward budding of the membrane of multivesicular endosomes. Thus, endosomes contain large quantities of endosome-associated proteins such as Rab GTPase SNAREs (soluble N-ethylmaleimide-sensitive fusion protein attachment protein receptors), Annexins and flotillin. In addition, CD63, CD81 and CD9 that belong to a membrane-spanning protein family are abundant in exosomes and can be used as markers for exosomes. In addition, heat shock proteins (HSP60, HSP70, HSP90), major histocompatibility complex (MHC) class I and II antigens and nucleic acids (DNA and RNA) are also contained.

Exosomes as well as microvesicles are involved in maintenance and regulation of vital functions of cells via cell-to-cell communication between cells in long-distance or between adjacent cells. In the immune system, for instance, it has been reported that exosomes released from T cells may modulate antigen-presentation functions of the antigen presenting cells by transferring miRNAs in the exosomes, by which immune responses are regulated [15]. On the other hand, regarding the mechanism of cancer cell metastasis, exosomes released from breast cancer have been shown to be capable of altering BBB, thereby enhancing the brain metastasis [16].

In the history of research for EVs, an important discovery was that they carry nucleic acids such as messenger RNAs (mRNAs) and miRNAs [17]. RNAs from donor cells may be selectively incorporated into EVs and delivered to recipient cells as messages from donor cells. Compared to mRNAs encoding polypeptide sequences, miRNAs are small non-coding RNAs of 21-23 nucleotides in length. miRNAs are incorporated into the RNA-induced silencing complex (RISC) and function as mediators in gene silencing. In this process, translation of mRNAs having partial complementarity to the miRNA is inhibited, whereas miRNAs carrying nearly complement sequences to the miRNA are digested [18, 19]. As such, miRNAs play important roles in gene regulation via suppression of their target genes in cells. Thousands of miRNA genes have been found in animals and plants, and expression profiling of miRNAs has revealed their tissue- and developmental stage-specific expression and also disease-associated expression[20-24]. Thus, miRNAs are closely related to various vital functions and pathogenesis of diseases via gene silencing, implying that they may serve as useful biomarkers or targets of therapy in human diseases.

Cells of different origin and characters produce EVs that contain different RNA repertoires. For instance, the exosomes from T, B, and dendritic immune cells are identified to contain miRNA repertoires characteristic for each cell population (15). Changes in EVs may represent...
altered homeostasis and become a useful marker for monitoring life maintenance systems and diseases.

3. EVs released by immune cells

The immune system is one of the complex and highly regulated systems in the human body. Almost every organ has its own immune protection system utilizing immune receptors, which are used to transmit external signals. Several communication modes like cell-cell interaction, cytokine signaling, and enzymatic reactions are known to be involved in the immune regulation. Researchers in the last two decades have shed light on the role of EVs in regulation of immune responses in normal and disease conditions [25-27].

Most of the immune cells can secrete EVs that control cellular response. For example, DCs secrete EVs at different stages of cellular activation, thereby regulating diverse functions of target cells. In fact, the large EVs of immature DCs induce T cell activation and also promote secretion of Th2 cytokines from the target T cells, whereas small EVs from the same cells induce Th1 cytokines. Both large and small EVs are capable of inducing IFN-γ secretion from T lymphocytes [28]. Another study showed that EVs derived from DCs contain cell surface molecules like MHC, ICAM-1 (Intercellular Adhesion Molecule 1) and some other costimulatory molecules that can promote an efficient induction of the T cell activation [29, 30].

EVs derived from T cells can also modulate the function of recipient cells. Exosomes/ectosomes derived from T cells may control the endothelial cells gene expression in CD47 dependent manner [31]. Recent studies showed that T cell-derived EVs controls B-cell responses and also have the potential to control the germline center reaction and antibody production [32, 33]. Key regulatory cells like Foxp3+ regulatory T cells (Tregs) also secrete EVs, which may regulate the production of IL-10 and IL-6 from DCs by utilizing miRNAs contained in the EVs [34]. Therefore, functions of EVs released from immune cells may depend on the physiological environment and types of cellular events.

4. Immune response and MS pathology

CNS inflammation is the primary damage taking place in the pathology of MS. Formation of demyelinating plaque in the CNS, which is caused by inflammatory processes, is a pathological hallmark of MS [35]. It is thought that autoreactive T cells, which recognize a CNS-derived peptide bound to MHC class II molecules, play a central role in the formation of CNS lesions. The T cells are activated in the periphery, then migrate to the CNS and produce inflammatory cytokines to damage the myelin and oligodendrocytes [36]. More recently, drugs targeting T cell migration have shown efficacy in MS, indicating the involvement of T cells in MS pathophysiology. Experimental autoimmune encephalomyelitis (EAE), a mouse model for human MS, is immensely used to explore the mechanism and pathophysiology of MS [37]. Experiments using EAE models have greatly helped the researchers to elucidate the roles of individual immune cells in the pathogenesis of MS and to identify potential targets of therapy or therapeutic strategies. T cells specific for a peptide capable of inducing EAE (such as myelin oligodendrocyte glycoprotein (MOG) 35-55) play a major role in EAE and are called encephalitogenic T cells. Encephalitogenic T cells contain Th1 cells which secrete IFN-γ and Th17 cells producing IL-17. Activated encephalitogenic T cells can pass through the BBB, reach the CNS and are reactivated in response to antigens presented by local antigen presenting cells, leading to the secretion of more cytokines to attract other immune cells like B cells, macrophages, and DCs. To some extent, these cells can also activate microglia and astrocytes in the CNS, which significantly contribute to inflammatory reactions [38-42].

5. The role of EVs in MS

EVs have diverse roles and broad targets, and individual EV appears to have its own mode of action, according to their origin. MS is the CNS autoimmune disease involving multiple inflammatory processes, which take place in the periphery, BBB and CNS parenchyma. Complex interactions between many immune cell types are found to occur in each process. EVs originated by immune cells may promote the progression of MS, but it is possible that they would also suppress the disease in a distinct manner [43]. Because of the versatility of EVs, we will discuss the various roles of EVs in MS at different subheadings.

5.1 EVs as pro-inflammatory regulator in MS

Exosomes play a potent role as a proinflammatory regulator in autoimmune diseases such as rheumatoid arthritis, Graves’ disease and MS [44-46]. The previous study indicated that microparticles from RRMS patients act together with inflammatory mediator thrombin to disrupt the endothelial barrier function, and the cargo inside the EVs may act as a proinflammatory signal in many circumstances [47-49]. In the EVs transfer experiments in mice model of MS, circulating plasma EVs of EAE mice induces the spontaneous relapse-remitting phenotype in MOG immunized mice, although this mouse model usually develops monophasic disease. Moreover, they showed that fibrinogen present in the transferred...
plasma EVs drives the CD8+ T cells which may contribute to induction of spontaneous EAE in transferred mice [50, 51]. In the study, B cells derived from MS patients were found to generate exosome enrichment factors with different protein content after in vitro culture. Interestingly, these factors have the potential to induce oligodendrocyte death but not death of microglia or astrocytes [52]. Our group has recently showed that exosomal miRNA in the plasma samples of MS patients can target regulatory T cells and disrupt the immune regulatory mechanism. In the study, we identified that miRNAs in the exosomes from RRMS are significantly altered as compared to exosomes from healthy subjects. In particular, an increase of miRNA let-7i was notable. Transferring the exosomes enriched with let-7i from MS patients to the naïve CD4+ T cells inhibit the differentiation of T reg cells [53]. These studies have indicated that EVs have the potential to regulate inflammatory responses in MS (Fig. 1(1)).

Figure 1. Role of EVs in Multiple sclerosis. (1) EVs act as proinflammatory regulator. EVs generated by immune cells in the periphery acts as proinflammatory signals for the activation of naïve immune cells that migrates and disrupt the CNS tissue. (2) EVs entering the CNS. EVs generated in periphery can cross the BBB and reaches the CNS tissue during inflammatory reaction. (3) EVs released from the CNS. EVs generated in CNS during inflammatory reaction will be released into the circulation. (4) EVs from Mesenchymal stem cells and Glial cells. EVs generated from MSC and Glial cell culture can reach the CNS inflammatory site and helps in remyelination of neurons.

5.2 EVs as biomarker in MS

EVs are considered to provide potential biomarkers for screening or monitoring of many diseases. Numerous efforts were made to evaluate the role of EVs as a biomarker for MS. In this regard, EVs content and surface markers are the major target in the past studies. Microparticles-concentration was found to greatly increase in plasma and cerebrospinal fluid (CSF) of MS patients, and then efforts were shifted to identify the phenotype of the EVs, enabling to track the possible generator of EVs. EVs containing surface CD31+ microparticles thought to be derived from endothelial cells of BBB, plasma platelet microparticles from circulating platelets, and CD4+/CCR3+ and CD4+/CCR5+ ones from the activated T cells were identified in plasma and CSF samples derived from MS patients by independent groups [54-57]. In the samples from MS patients, there were also EVs containing myelin proteins like MBP (myelin basic protein), PLP (proteolipid protein), and MOG. Presence of these proteins was confirmed in exosomes derived from serum, CSF, and peripheral blood mononuclear cells. The amount of MOG in the exosome strongly correlated with disease activity [58]. Particle size distribution of plasma EVs in MS patients differs from that of healthy individuals, and mass spectroscopy analysis of small EVs from the MS patients has showed increased C16:0 sulfatide (sulfatide with short chain fatty acid) that can be a biomarker for MS [59]. Another study was carried out to evaluate differential surface protein expression in MS. Interestingly, serum EVs from RRMS showed the increased TLR4 and
there were higher numbers of acid sphingomyelinase-enriched exosomes in the CSF of MS, which well correlated to enzymatic activity and to disease severity of MS [62]. Although several groups have tried to identify an EV biomarker relevant for MS, such efforts have not been successful. We speculate that circulating EVs could be generated and released by CNS cells. But, it is also possible that EVs released from the peripheral tissue may cross the BBB and enter the CNS tissue (Fig. 1(2, 3)). Assuming this, it seems to be rewarding to pursue efforts to seek for a biomarker useful for diagnosis and management of MS (Table 1).

### Table 1. EVs as a biomarker in MS.

| Disease Progression | EVs Marker | Source | Reference |
|----------------------|------------|--------|-----------|
| RRMS/SPMS            | CD4+CCR3* and CD4+CCR5* | CSF | (54) |
| CIS/RRMS/SPMS        | CD31+ Endothelial microparticles | Plasma | (55, 56) |
| RRMS                 | plasma platelet microparticles | Plasma | (57) |
| RRMS/SPMS            | myelin basic protein, proteolipid protein, and myelin oligodendrocyte glycoprotein | Plasma CSF PBMC | (58) |
| SPMS                 | C16:0 sulfatide | Plasma | (59) |
| RRMS                 | TLR4 | Serum | (60) |
| RRMS                 | kallikrein and Apolipoprotein-E4 | CSF | (61) |
| RRMS/CIS/PCP         | acid sphingomyelinase | CSF | (62) |

#### 5.3 Exosomes (Small EVs) in MS

Exosomes are the class of small EVs released by various cell types, and has a wide variety of application in biology [63, 64]. Exosomes derived from the CNS cells could be released into blood stream and circulate throughout the body. In vitro experiments have also indicated that they have potentials to cross the BBB [65, 66]. Most of the EVs are enriched with small RNAs, possessing the ability to control a variety of physiological processes. Exosome-associated miRNAs are one of the major candidates that can control expression of mRNA and can be the biomarker for human diseases. Studies of serum samples from MS patients showed that several exosomal miRNAs are differentially expressed, depending on disease activity and progression status. Techniques such as microarrays, next generation sequencing, and real time expression analysis have contributed to profiling the exosomal miRNAs. Several groups including ours have already reported differentially expressed EVs mRNA in MS. As described above, Kimura and colleague have shown the up-regulation of miR-let-7i, miR-19b, miR-25, and miR-92a in circulating exosomes in patients with RRMS. Of the miRNAs, the expression of miR-let7i was increased in MS, and moreover, the miRNA can potentially suppress the immune regulation mediated by Treg cells. Mechanistically, miR-let7i suppresses the generation of Treg by targeting insulin like growth factor 1 receptor (IGF1R) and transforming growth factor beta receptor 1 (TGFBR1). Consistently, IGF1R and TGFBR1 expressed on circulating naive CD4+ T cells is reduced in patients with MS [67].

In another study, miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p were shown to be dysregulated in RRMS patients, whereas miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p were dysregulated in patients with secondary progressive MS (SPMS) as compared with healthy controls. When the miRNA from EVs of the two different stages of MS, namely RRMS and SPMS, was compared, miR-15b-5p, miR-23a-3p, miR-223-3p, miR-37a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, and miR-432-5p were greatly dysregulated [68]. In the study by Selmaj et al., RRMS patients showed up-regulated miR-196b-5p, miR-301a-3p, and miR-532-5p and down-regulated miR-122-5p, miR-196b-5p, miR-301a-3p, and miR-532-5 in circulating plasma exosomes [69]. The other study on CSF samples showed that MS patients have increased amounts of miR-146a-5p, miR-181a and miR-223 [70] (Table 2).
In summary, small EVs are filled with various contents that have different roles individually in the progression of disease, which can modulate the gene expression in the target cells. Therefore, increases of small EVs in MS may have a direct impact on pathogenesis (Fig. 1(2.3)).

Table 2. Small EVs (Exosomes) and their microRNA content in MS.

| Disease Progression | Dysregulated miRNA                                                | Derived from         | Reference |
|---------------------|--------------------------------------------------------------------|----------------------|-----------|
| RRMS/SPMS vs HC     | Up regulated miR-let-7i, miR-19b, miR-25, miR-92a                  | Circulating exosomes | (67)      |
| RRMS vs HC          | miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p                       | Circulating exosomes | (68)      |
| SPMS vs HC          | miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p                    | Circulating exosomes |           |
| RRMS vs SPMS        | miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p | Circulating exosomes | (69)      |
| RRMS vs HC          | Up regulated miR-196b-5p, miR-301a-3p and miR-532-5p              | Circulating exosomes |           |
|                     | Down regulated miR-122-5p, miR-196b-5p, miR-301a-3p, and miR-532-5p | CSF exosomes         | (70)      |
| MS vs HC            | Up regulated miR-146a-5p, miR-181a and miR-223                    | CSF exosomes         |           |

5.4 EVs in MS therapy

In another approach for research, EVs are regarded as therapeutic targets or reagents in treating human diseases, including MS [71]. Some recent studies have shown that EVs derived from mesenchymal stem cells (MSCs) of adipose tissue would promote recovery from demyelination in an animal model for progressive MS. Notably, transfer of MSCs has been evaluated for years as cell therapy for MS. As the outcome of transferring EVs from MSC, they observed microglial polarization, up-regulation of CD4⁺CD25⁺FOXP3⁺ regulatory T cells (Treg), and a reduction in plasma proinflammatory cytokines. In *in vitro* analysis showed that exosomes derived from MSCs stimulated by IFN-γ are able to suppress T cell proliferation, and Th1 and Th17 cytokine production including IL-6, IL-12p70, IL-17AF, and IL-22 in an *in vitro* culture, though they increased the levels of indoleamine 2,3-dioxygenase, a known anti-inflammatory enzyme. In addition, MSC-exosomal derived miRNA can control the microglial polarization towards M1 or M2 phenotype along with altering cytokine profiles [72-75]. EVs can be engineered to carry desired cargo and to deliver it at specific target site, Casella et al. recently developed murine microglial cell line that produces EVs that express endogenous “eat me” signal Lactadherin (Mfg-e8) on the surface and are filled with IL-4. A single injection of the engineered EV reduced neuro-inflammation in the mice induced for EAE, and the EAE clinical score was reduced associated with up-regulation of anti-inflammatory markers in phagocytic cells [76]. Recently the same group have shown that, naturally derived EVs from oligodendrocytes culture contains myelin antigens and transfer of this EVs reduce EAE pathophysiology in a myelin antigen-dependent manner in EAE models [77]. Interestingly EVs derived from MSC protects oligodendrocytes from DNA damage and EVs from MSC co-cultured with microglia helps the myelin repair by recruiting oligodendrocyte precursor (OPC) in demyelinated regions[78, 79].

It is widely known that relapse frequency of MS is markedly reduced in pregnant women with MS [80]. Williams and his colleague have looked into the involvement of EVs in EAE model and reported that levels of circulating exosomes are increased during pregnancy and an injection of the exosomes into EAE mice suppresses T cell activation and helps the maturation and migration of oligodendrocyte precursor cells (OPC) into active lesions [81]. Taken together, EVs generated from MSC, microglia and oligodendrocytes have a potential to treat demyelination lesions or restoring immune tolerance in MS (Fig. 1(4)) (Table 3). Even though EVs have shown a promising result in treatment of MS, there are some lacunas before completely understanding their therapeutic, biological and functional properties. Further comprehensive research is required to make EVs as therapeutic agents in MS treatment.

5.5 EVs as a therapeutic biomarker in MS

Fingolimod is a first-in-class orally bioavailable drug used to treat MS. Fingolimod in the phosphorylated form binds to the lymphocytes S1P1 receptor with high-affinity, thus preventing egress of lymphocytes from the secondary lymphoid organs and entry of pathogenic T cells into the CNS of MS patients [82]. Analysis of
fingolimod-treated MS patients showed dramatic changes in the concentration of EVs and their miRNA content with altering immune regulatory activity within 5 h after fingolimod administration [83]. Another challenge in treatment of MS is for many patients with MS who are not responsive to available drugs [84]. In this view, Manna et al. has shown interesting results, indicating that two exosome-associated miRNAs expression might be utilized in identifying IFN-β response groups. In relation with this, miR-22-3p and miR-660-5p were significantly up-regulated and about 14 miRNAs were downregulated in IFN-β – treated RRMS patients with response to therapy compared to those without response [85]. Therefore, in future there are possibilities of adopting EVs evaluation as standard biomarker for prediction or early decision for the drug efficacy in individual MS patients.

Table 3. EVs in MS therapy.

| EVs origin                          | Target                                         | Result                                      | Reference |
|-------------------------------------|------------------------------------------------|---------------------------------------------|-----------|
| MSCs from human adipose tissue      | Reduced glial fibrillary acidic protein and Iba-1 in brain | Diminishing brain atrophy and promoting remyelination | (72)      |
| MSCs stimulated by IFNγ             | Reduced IL-6, IL-12p70, IL-17AF, and IL-22     | Upregulates regulatory T cells numbers      | (73)      |
| Bone marrow MSCs                    | Increases in IL-10, TGF-β, Decreases TNF-α, IL-12 | Regulating the polarization of microglia     | (74, 75)  |
| Microglia                           | upregulating anti-inflammatory markers in phagocytic cells | Reduced Neuroinflammation                  | (76)      |
| Oligodendrocytes                    | Induce immunosuppressive monocytes and apoptosis of autoreactive CD4+ T cells | Reduced EAE pathophysiology                | (77)      |
| Placenta-derived Mesenchymal stem/stromal cells | Reduced DNA damage in oligodendroglia populations | Increased myelination in Spinal cord        | (78)      |
| Microglia co-cultured with MSCs     | Promoted oligodendrocyte precursor cells recruitment | Myelin repair                              | (79)      |

6.0 Limitations and Future prospective

Since most of the cells shed the EVs in normal physiological process, EVs are widely distributed throughout the body fluids. Therefore, categorization of EVs based on their origin, targets or function is still a challenge. Although EVs research requires detailed and deep studies to confirm their role in disease pathophysiology, MS is an autoimmune disorder influenced by multiple genetic and environmental factors, which would hamper the research into the role of EVs in MS. The past analysis showed that EVs from MS patients’ blood samples contains proteins and miRNA’s targeting BBB and regulatory T cells differentiation. Nevertheless, it is obvious that more concrete evidence is required to establish their role in MS pathophysiology. Several research groups have tried to correlate the characters of circulating EVs in MS patients with those in EAE model mouse, with a purpose to utilize the EVs as a signature biomarker in MS screening. Unfortunately, there was nonconsistency in the results, possibly due to the influence of environmental and genetic factors. However, more robust and detailed studies on EVs surface molecules and their cargo considering several influencing factors may help to identify the candidate signature in MS disease activity and progression.

Because of the circulating property, EVs has been considered as a future therapeutic delivery system. In fact, *in vivo* injections of EVs generated from MSC of several tissue types and healthy glial cells like microglia and oligodendrocytes have remarkably reduced the inflammatory reactions in EAE models. Also, efforts to generate engineered EVs with desired peptide cargo to target pathogenic cells were successful and proved to be efficacious in prevention of EAE model. Given such promising data, we believe that more efforts on this direction to relay on EVs as a therapeutic agent will be rewarding for future treatments of MS.

7.0 Conclusion

The cause and pathogenesis of MS is still not clear, but several efforts to stop the progression of MS with drugs resulted in making significant progress. Given the circulating properties of EVs along with the surface bound receptors and cargo contents, EVs may have a significant role in the immune cell signaling involved in MS progression. Because of the potentiality of EVs contents
like miRNAs to regulate mRNA expression, EVs may become a potential biomarker in diagnosing and monitoring the disease progression and also can be a therapeutic target in MS treatment. Since their regulatory mechanisms would be worked in several levels in a complicated manner, more extensive studies to analyze EVs carefully and to elucidate their role in connection to MS pathogenesis and treatment are needed in the future.

Acknowledgments

MSM is thankful for the support by Multiple Sclerosis International Federation (MSIF) through McDonald fellowship sponsored by ARSEP. We would like to thank Dr. Kimitoshi Kimura for his helpful advice. This work was supported by the practical research project for rare/intractable diseases from Japan Agency for Medical Research and Development (AMED) (Grant #:17ek0109190h0002; 20ek0109315h0003) and AMED-Core Research for Evolutional Science and Technology (CREST) (Grant #:18gm1010011h0001; 19gm1010011h0002).

Conflict of interest

Authors declare no conflict of interest.

References

[1] Gandhi R, Laroni A, Weiner HL (2010). Role of the innate immune system in the pathogenesis of multiple sclerosis. Journal of Neuroimmunology, 221:7-14.
[2] El Behi M, Dubucquoi S, Lefranc D, Zéphir H, De Seze J, Vermersch P, et al. (2005). New insights into cell responses involved in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunol Lett, 96:11-26.
[3] Van Kaer L, Postoak JL, Wang C, Yang G, Wu L (2019). Innate, innate-like and adaptive lymphocytes in the pathogenesis of MS and EAE. Cell Mol Immunol, 16:531-539.
[4] Ponath G, Park C, Pitt D (2018). The Role of Astrocytes in Multiple Sclerosis. Front Immunol, 9:217.
[5] Traiffort E, Kassoussi A, Zahaf A, Laouarem Y (2020). Astrocytes and Microglia as Major Players of Myelin Production in Normal and Pathological Conditions. Frontiers in Cellular Neuroscience, 14.
[6] Ludwin SK, Rao V, Moore CS, Antel JP (2016). Astrocytes in multiple sclerosis. Mult Scier, 22:1114-1124.
[7] Lécuyer MA, Kebrir H, Prat A (2016). Glial influences on BBB functions and molecular players in immune cell trafficking. Biochim Biophys Acta, 1862:472-482.
[8] Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O (2018). Multiple sclerosis. The Lancet, 391:1622-1636.
[9] Olsson T, Barcellos LF, Alfredsson L (2017). Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nature Reviews Neurology, 13:25-36.
[10] Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, et al. (2011). Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature, 476:214-219.
[11] Munger KL, Köchert K, Simon KC, Kappos L, Polman CH, Freedman MS, et al. (2014). Molecular mechanism underlying the impact of vitamin D on disease activity of MS. Ann Clin Transl Neurol, 1:605-617.
[12] Navid F, Bruhs A, Schuller W, Fritsche E, Krutmann J, Schwarz T, et al. (2013). The Aryl hydrocarbon receptor is involved in UVR-induced immunosuppression. J Invest Dermatol, 133:2763-2770.
[13] Procaccini C, Pucino V, Mantzoros CS, Matarese G (2015). Leptin in autoimmune diseases. Metabolism, 64:92-104.
[14] Buzas E, György B, Nagy G, Falus A, Gay S (2014). Emerging role of extracellular vesicles in inflammatory diseases. Nature Reviews Rheumatology, 10:356-364.
[15] Mittelbrunn M, Gutiérrez-Vázquez C, Villarroya-Beltri C, González S, Sánchez-Cabo F, González M, et al. (2011). Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. Nat Commun, 2:282.
[16] Tominaga N, Kosaka N, Ono M, Katsuda T, Yoshioka Y, Tamura K, et al. (2015). Brain metastatic cancer cells release microRNA-181c-containing extracellular vesicles capable of destructing blood-brain barrier. Nat Commun, 6:6716.
[17] Yáñez-Mó M, Siljander PRM, Andreu Z, Bedina Zavec A, Borrás FE, Buzas EI, et al. (2015). Biological properties of extracellular vesicles and their physiological functions. Journal of Extracellular Vesicles, 4:27066.
[18] Krol J, Loedige I, Filipowicz W (2010). The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet, 11:597-610.
[19] Carthew RW, Sontheimer EJ (2009). Origins and Mechanisms of miRNAs and siRNAs. Cell, 136:642-655.
[20] Fukuoka M, Takahashi M, Fujita H, Chiyo T, Popiel HA, Watanabe S, et al. (2018). Supplemental Treatment for Huntington's Disease with miR-132 that Is Deficient in Huntington's Disease Brain. Mol Ther Nucleic Acids, 11:79-90.
[21] Eda A, Takahashi M, Fukushima T, Hohjoh H (2011). Alteration of microRNA expression in the process of mouse brain growth. Gene, 485:46-52.
[22] Hohjoh H, Fukushima T (2007). Expression profile analysis of microRNA (miRNA) in mouse central nervous system using a new miRNA detection system that examines hybridization signals at every step of washing. Gene, 391:39-44.
[23] Hohjoh H, Fukushima T (2007). Marked change in microRNA expression during neuronal differentiation of human teratocarcinoma NTera2D1 and mouse embryonal carcinoma P19 cells. Biochem Biophys Res Commun, 362:360-367. 

[24] Lagos-Quintana M, Rauhut R, Yalcin A, Meyer J, Lendeckel W, Tuschl T (2002). Identification of tissue-specific microRNAs from mouse. Curr Biol, 12:735-739. 

[25] Pusic KM, Pusic AD, Kraig RP (2016). Environmental Enrichment Stimulates Immune Cell Secretion of Exosomes that Promote CNS Myelination and May Regulate Inflammation. Cell Mol Neurobiol, 36:313-325. 

[26] Howitt J, Hill AF (2016). Exosomes in the Pathology of Neurodegenerative Diseases. J Biol Chem, 291:26589-26597. 

[27] D’Anca M, Fenoglio C, Serpente M, Arosio B, Cesari M, Scarpini EA, et al. (2019). Exosome Determinants of Physiological Aging and Age-Related Neurodegenerative Diseases. Front Aging Neurosci, 11:232. 

[28] Tkach M, Kowal J, Zucchetti AE, Enserink L, Jouve M, Lankar D, et al. (2017). Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. The EMBO Journal, 36:3012-3028. 

[29] Théry C, Duban L, Segura E, Vérone P, Lantz O, Amigorena S (2002). Indirect activation of naïve CD4+ T cells by dendritic cell-derived exosomes. Nat Immunol, 3:1156-1162. 

[30] Segura E, Nicco C, Lombard B, Vérone P, Raptopo G, Batteux F, et al. (2005). ICAM-1 on exosomes from mature dendritic cells is critical for efficient naïve T-cell priming. Blood, 106:216-223. 

[31] Kaur S, Singh SP, Elkahloung AG, Wu W, Abu-Asab MS, Roberts DD (2014). CD47-dependent immunomodulatory and angiogenic activities of extracellular vesicles produced by T cells. Matrix Biol, 37:49-59. 

[32] Fernández-Messina L, Rodríguez-Galán A, de Yébenes VG, Gutiérrez-Vázquez C, Tenreiro S, Sebra MC, et al. (2020). Transfer of extracellular vesicle-microRNA controls germinal center reaction and antibody production. EMBO Rep, 21:e48925. 

[33] Yang J, Dang G, Lü S, Liu H, Ma X, Han L, et al. (2019). T-cell-derived extracellular vesicles regulate B-cell IgG production via pyruvate kinase muscle isozyme 2. Faseb j, 33:12780-12799. 

[34] Tung SL, Boardman DA, Sen M, Letizia M, Peng Q, Cianci N, et al. (2018). Regulatory T cell-derived extracellular vesicles modify dendritic cell function. Sci Rep, 8:6065. 

[35] Frohman EM, Racke MK, Raine CS (2006). Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med, 354:942-955. 

[36] Compton A, Coles A (2008). Multiple sclerosis. Lancet, 372:1502-1517. 

[37] Fletcher JM, Lalor SJ, Sweeney CM, Tubridy N, Mills KH (2010). T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol, 162:1-11. 

[38] McFarland HF, Martin R (2007). Multiple sclerosis: a complicated picture of autoimmunity. Nat Immunol, 8:913-919. 

[39] Barnett MH, Henderson AP, Prineas JW (2006). The macrophage in MS: just a scavenger after all? Pathology and pathogenesis of the acute MS lesion. Mult Scler, 12:121-132. 

[40] Bettelli E, Korn T, Oukka M, Kuchroo VK (2008). Induction and effector functions of T(H)17 cells. Nature, 453:1051-1057. 

[41] Baeche-Allan C, Kaskow BJ, Weiner HL (2018). Multiple Sclerosis: Mechanisms and Immunotherapy. Neuron, 97:742-768. 

[42] Wu GF, Alvarez E (2011). The immunopathophysiology of multiple sclerosis. Neur Clin, 29:257-278. 

[43] Sáenz-Cuesta M, Osorio-Queijeta I, Otaegui D (2014). Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? Front Cell Neurosci, 8:100. 

[44] Duan W, Zhang W, Jia J, Lu Q, Eric Gershwin M (2019). Exosomal microRNA in autoimmunity. Cellular & Molecular Immunology, 16:932-934. 

[45] Tan L, Wu H, Liu Y, Zhao M, Li D, Lu Q (2016). Recent advances of exosomes in immune modulation and autoimmune diseases. Autoimmunity, 49:357-365. 

[46] Meng Q, Qiu B (2020). Exosomal MicroRNA-320a Derived From Mesenchymal Stem Cells Regulates Rheumatoid Arthritis Fibroblast-Like Synoviocyte Activation by Suppressing CXCL9 Expression. Frontiers in Physiology, 11. 

[47] Gener Lahav T, Adler O, Zait Y, Shani O, Amer M, Doron H, et al. (2019). Melanoma-derived extracellular vesicles instigate proinflammatory signaling in the metastatic microenvironment. International Journal of Cancer, 145:2521-2534. 

[48] Mitsushashi S, Feldbrügge L, Csizmadia E, Mitsushashi M, Robson SC, Moss AC (2016). Luminal Extracellular Vesicles (EVs) in Inflammatory Bowel Disease (IBD) Exhibit Proinflammatory Effects on Epithelial Cells and Macrophages. Inflammatory Bowel Diseases, 22:1587-1595. 

[49] Youn YJ, Shrestha S, Lee YB, Kim JK, Lee JH, Hur K, et al. (2021). Neutrophil-derived trail is a proinflammatory subtype of neutrophil-derived extracellular vesicles. Theranostics, 11:2770-2781. 

[50] Willis CM, Nicaise AM, Menoret A, Ryu JK, Mendiola AS, Jellison ER, et al. (2019). Extracellular vesicle fibrinogen induces endophagocytic CD8+ T cells in a mouse model of multiple sclerosis. Proc Natl Acad Sci U S A, 116:10488-10493. 

[51] Marcos-Ramiro B, Oliva Nacarino P, Serrano-Pertierra E, Blanco-Gelaz MA, Weksler BB, Romero IA, et al. (2014). Microparticles in multiple sclerosis and clinically isolated syndrome: effect on endothelial barrier function. BMC Neurosci, 15:110. 

[52] Benjamins JA, Nedelkoska L, Touil H, Stemmer PM, Carruthers NJ, Jena BP, et al. (2019). Exosome-enriched fractions from MS B cells induce oligodendrocyte death. Neurrol Neuroimmunool
Neuroinflamm, 6:e550.

[53] Kimura K, Hohjoh H, Yamamura T (2018). The Role for Exosomal microRNAs in Disruption of Regulatory T Cell Homeostasis in Multiple Sclerosis. J Exp Neurossi, 12:1179069518764892.

[54] Geraci F, Ragonese P, Barreca MM, Aliotta E, Mazzola MA, Realmuto S, et al. (2018). Differences in Intercellular Communication During Clinical Relapse and Gadolinium-Enhanced MRI in Patients With Relapsing Remitting Multiple Sclerosis: A Study of the Composition of Extracellular Vesicles in Cerebrospinal Fluid. Frontiers in Cellular Neuroscience, 12.

[55] Minagar A, Jy W, Jimenez JJ, Shermata WA, Mauro LM, Mao WW, et al. (2001). Elevated plasma endothelial microparticles in multiple sclerosis. Neurology, 56:1319-1324.

[56] Alexander JS, Chervenak R, Weinstock-Gutman B, Tsunoda I, Ramanathan M, Martinez N, et al. (2015). Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes. J Neurol Sci, 355:84-89.

[57] Shermata WA, Jy W, Horstman LL, Ahn YS, Alexander JS, Minagar A (2008). Evidence of platelet activation in multiple sclerosis. Journal of Neuroinflammation, 5:27.

[58] Galazka G, Mycko MP, Selmaj I, Raine CS, Selmaj KW (2018). Multiple sclerosis: Serum-derived exosomes express myelin proteins. Mult Scler, 24:449-458.

[59] Moyano AL, Li G, Bouillerne AI, Feinstein DL, Hartman E, Skias D, et al. (2016). Sulfatides in extracellular vesicles isolated from plasma of multiple sclerosis patients. J Neurosci Res, 94:1579-1587.

[60] Bhargava P, Nogueiras-Ortiz C, Chawla S, Bæk R, Jørgensen MM, Kapoigianis D (2019). Altered Levels of Toll-Like Receptors in Circulating Extracellular Vesicles in Multiple Sclerosis. Cells, 8.

[61] Welton JL, Loveless S, Stone T, von Ruhland C, Robertson NP, Clayton A (2017). Cerebrospinal fluid extracellular vesicle enrichment for protein biomarker discovery in neurological disease; multiple sclerosis. J Extracell Vesicles, 6:1369805.

[62] Pieragostino D, Cicalini I, Lanuti P, Ercolino E, di Ioia M, Zucchelli M, et al. (2018). Enhanced release of acid sphingomyelinase-enriched exosomes generates a lipodomics signature in CSF of Multiple Sclerosis patients. Sci Rep, 8:3071.

[63] Kalluri R, LeBlue VS (2020). The biology of exosomes: an emerging field of biomedicine and biomedicine applications of exosomes. Science, 367:eaau6977.

[64] Luan X, Sansanaphongpircha K, Myers I, Chen H, Yuan H, Sun D (2017). Engineering exosomes as refined biological nanoplatforms for drug delivery. Acta Pharmacologica Sinica, 38:754-763.

[65] Hornung S, Dutta S, Bitan G (2020). CNS-Derived Blood Exosomes as a Promising Source of Biomarkers.

[66] Opportunities and Challenges. Frontiers in Molecular Neuroscience, 13.

[67] Kimura K, Hohjoh H, Fukuoka M, Sato W, Oku S, Tomi C, et al. (2018). Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis. Nature Communications, 9.

[68] Ebrahimkhani S, Vafaee F, Young PE, Hur SSI, Hawke S, Devenney E, et al. (2017). Exosomal microRNA signatures in multiple sclerosis reflect disease status. Scientific Reports, 7.

[69] Sélmaï I, Cichalewska M, Namiecinśka M, Galazka G, Horzel W, Selmaj KW, et al. (2017). Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann Neurol, 81:703-717.

[70] Prada I, Gabrielli M, Turola E, Iorio A, D’Arrigo G, Parolisi R, et al. (2018). Glia-to-neuron transfer of miRNAs via extracellular vesicles: a new mechanism underling inflammation-induced synaptic alterations. Acta Neuropathol, 135:529-550.

[71] Osorio-Querejeta I, Alberro A, Muñoz-Culla M, Mäger I, Otaegui D (2018). Therapeutic Potential of Extracellular Vesicles for Demyelinating Diseases; Challenges and Opportunities. Front Mol Neurosci, 11:434.

[72] Laso-García F, Ramos-Cejudo J, Carrillo-Salinas FJ, Otero-Ortega L, Feliú A, Gómez-de Frutos M, et al. (2018). Therapeutic potential of extracellular vesicles derived from human mesenchymal stem cells in a model of progressive multiple sclerosis. PLoS One, 13:e0202590.

[73] Riaziifar M, Mohammadi MR, Pone EJ, Yeri A, Lässer C, Segaliny AI, et al. (2019). Stem Cell-Derived Exosomes as Nanotherapeutics for Autoimmune and Neurodegenerative Disorders. ACS Nano, 13:6670-6688.

[74] Li Z, Liu F, He X, Yang X, Shan F, Feng J (2019). Exosomes derived from mesenchymal stem cells attenuate inflammation and demyelination of the central nervous system in EAE rats by regulating the polarization of microglia. Int Immunopharmacol, 67:268-280.

[75] Gomzikova MO, James Y, Rizvanov AA (2019). Therapeutic Application of Mesenchymal Stem Cells Derived Extracellular Vesicles for Immunomodulation. Front Immunol, 10:2663.

[76] Casella G, Colombo F, Finardi A, Descamps H, Spinelli A, et al. (2018). Extracellular Vesicles Containing IL-4 Modulate Neuroinflammation in a Mouse Model of Multiple Sclerosis. Mol Ther, 26:2107-2118.

[77] Casella G, Rasouli J, Boehm A, Zhang W, Xiao D, Ishikawa LLW, et al. (2020). Oligodendrocyte-derived extracellular vesicles as antigen-specific therapy for autoimmune neuroinflammation in mice. Science Translational Medicine, 12:eaba0599.

[78] Clark K, Zhang S, Barthe S, Kumar P, Rivetti C,
Kreutzberg N, et al. (2019). Placental Mesenchymal Stem Cell-Derived Extracellular Vesicles Promote Myelin Regeneration in an Animal Model of Multiple Sclerosis. Cells, 8.

Lombardi M, Parolisi R, Scaroni F, Bonfanti E, Gualerzi A, Gabrielli M, et al. (2019). Detrimental and protective action of microglial extracellular vesicles on myelin lesions: astrocyte involvement in remyelination failure. Acta Neuropathol, 138:987-1012.

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T (1998). Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med, 339:285-291.

Williams JL, Gatson NN, Smith KM, Almad A, McTigue DM, Whitacre CC (2013). Serum exosomes in pregnancy-associated immune modulation and neuroprotection during CNS autoimmunity. Clinical Immunology, 149:236-243.

Chun J, Hartung HP (2010). Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol, 33:91-101.

Sáenz-Cuesta M, Alberro A, Muñoz-Culla M, Osorio-Querejeta I, Fernandez-Merlado M, Lopetegui I, et al. (2018). The First Dose of Fingolimod Affects Circulating Extracellular Vesicles in Multiple Sclerosis Patients. Int J Mol Sci, 19.

Martinez-Forero I, Pelaye A, Villoslada P (2008). Pharmacogenomics of multiple sclerosis: in search for a personalized therapy. Expert Opin Pharmacother, 9:3053-3067.

Manna I, Iaccino E, Dattilo V, Barone S, Vecchio E, Mimmi S, et al. (2018). Exosome-associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. The FASEB Journal, 32:4241-4246.